Mallinckrodt, Endo set for $6.7B merger
Merger Overview
- Mallinckrodt and Endo have agreed to merge in a $6.7 billion cash and stock deal13
- The combined company will be a global, diversified pharmaceuticals leader7
- Expected to close in the second half of 2025, subject to shareholder and regulatory approvals13
Key Facts
- Combined 2025 revenue projected at $3.6 billion13
- Headquarters will be in Dublin, Ireland (Mallinckrodt's current HQ)14
- Will be listed on the New York Stock Exchange3
- 5,700 employees, 17 manufacturing facilities, 30 distribution centers globally1
Ownership Structure
- Mallinckrodt shareholders will own 50.1% of combined company
- Endo shareholders will receive $80 million cash and own 49.9%13
Leadership
- Siggi Olafsson (current Mallinckrodt CEO) will be CEO of combined company
- Paul Efron (Endo board member) will be Chairman34
Strategic Rationale
- Combine complementary portfolios and capabilities
- Generate $150 million in annual synergies by year 3
- Greater scale and resources to invest in growth opportunities37
Post-Merger Plans
- Intend to combine and later separate their generics businesses and Endo's sterile injectables business37
Sources:
1. https://www.genengnews.com/topics/drug-discovery/mallinckrodt-endo-plan-6-7b-merger/
3. https://medcitynews.com/2025/03/mallinckrodt-endo-merger-acquisition-ndoi/
4. https://www.bizjournals.com/philadelphia/news/2025/03/13/endo-mallinckrodt-merger-xiaflex.html
7. https://www.biospace.com/press-releases/mallinckrodt-and-endo-to-combine-to-create-a-global-scaled-diversified-pharmaceuticals-leader